Money for Medication: A randomized controlled study on the effectiveness of financial incentives to improve medication adherence in patients with a psychotic disorder and comorbid substance abuse.

Recruiting

Conditions: 1. Disorder in the perception of reality
2. Disorder with periods of hallucinations
delusions or disorganization
10039628

Registration Number: NL-OMON34809

Lead Sponsor: Parnassia Bavo Groep (Den Haag)

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 168

Inclusion Criteria

1. Age between 18 - 65 years
2. Psychotic disorder (including schizophrenia, schizoaffective disorder or other psychotic disorders)
3. Substance use disorder (alcohol and/or drugs)
4. An indication for antipsychotic depot medication
5. Outpatient treatment (either starting outpatient treatment or being in outpatient treatment for at least four months and having missed at least 50% (cf. Priebe, 2009) of prescribed depot medications).
6. Have given informed consent

Exclusion Criteria

1. Not meeting all inclusion criteria
2. Inability to participate in this study due to cognitive impairments
3. Inability to understand the Dutch language sufficiently to participate in this study

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary outcome measure of the current study is the number (percentage) of<br /><br>accepted depot injections. This number is defined as the Medication Possession<br /><br>Ratio (MPR) first reported by Sclar, Chin and Skaer (1991). The MPR is the<br /><br>number of accepted depots antipsychotic medication divided by the number of<br /><br>prescribed depots antipsychotic medication (the number of supplies needed for<br /><br>continuous use of antipsychotic medication).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Our secondary outcome measures include the longest period of uninterrupted<br /><br>depot acceptance, the time expired before the depot is taken, the number of<br /><br>admissions in psychiatric hospitals, the effort initiated by the clinicians to<br /><br>provide the depot, patients symptomatology, social and psychological<br /><br>functioning, substance abuse, subjective quality of life and subjective<br /><br>wellbeing under neuroleptics. We will also assess cost-effectiveness of M4M<br /><br>from a societal perspective. Furthermore, we will explore how medication<br /><br>acceptance is related to impulsivity, patients attitudes towards medication and<br /><br>we will explore patients and clinicians attitudes towards M4M. </p><br>